カテゴリー： Allied Market Research, 世界, 医療/バイオ

僧帽弁疾患治療薬の世界市場2023-2032：機会分析・産業予測

◆英語タイトル：Mitral Valve Disease Therapeutics Market By Drug class (Beta blockers, Diuretics, Anticoagulants, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Researchが発行した調査報告書（ALD23SEP151）◆商品コード：ALD23SEP151
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2023年5月
◆ページ数：268
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：生命科学
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

僧帽弁疾患治療薬市場は、2022年に6億774万ドルと評価され、2023年から2032年までの年平均成長率は2.8%を示し、2032年には8億344万ドルに達すると予測されています。僧帽弁疾患は、心臓の左心房と左心室の間にある僧帽弁に影響を及ぼす疾患です。僧帽弁は、血液が左心房から左心室へ確実に流れるよう、心臓内の血流を調節する働きをします。一般的な僧帽弁疾患には、僧帽弁閉鎖不全症、僧帽弁狭窄症、僧帽弁逸脱症などがあります。僧帽弁閉鎖不全症では、弁が適切に閉じず、血液が左心房に逆流します。
さらに僧帽弁狭窄症では、弁が狭くなって血液が流れにくくなります。僧帽弁逸脱症では、心臓の収縮時に弁尖が左心房内に膨らみ、血液が逆流することがあります。僧帽弁疾患には、倦怠感、心雑音、不整脈、息切れなどの症状があります。そのため、β遮断薬、利尿薬、抗凝固薬などの適切な薬剤を使用して症状を管理し、心臓機能を改善します。

僧帽弁疾患治療薬市場の成長を促す主な要因は、僧帽弁疾患の有病率の増加です。僧帽弁閉鎖不全症、僧帽弁逸脱症、僧帽弁狭窄症などの僧帽弁疾患と診断される患者数が増加しています。例えば、Journal of Clinical Medicine 2022によると、僧帽弁閉鎖不全症はヨーロッパで2番目に多く、アメリカでは最も多い心臓弁膜症であり、75歳以上の人口における有病率は9.3%です。したがって、僧帽弁疾患の有病率の増加は、治療薬に対する需要をもたらし、市場の成長を促進します。

さらに、僧帽弁疾患は、リウマチ熱や先天性心疾患などの様々な要因によって引き起こされる可能性があります。リウマチ熱は溶連菌感染後に発症する炎症性疾患で、炎症が心臓に広がり、僧帽弁を含む心臓弁に損傷を与えます。この損傷が僧帽弁疾患を引き起こし、息切れ、疲労感、胸痛、動悸などの症状を引き起こします。また、先天性心疾患は生まれつきの構造異常です。一部の先天性心疾患は僧帽弁の機能に影響を及ぼし、僧帽弁疾患を引き起こします。そのため、僧帽弁疾患の症状を管理するために、β遮断薬、利尿薬、カルシウム拮抗薬などの治療薬が処方され、市場の成長を促進しています。
さらに、僧帽弁置換術の増加や治療薬の採用が市場の成長を促進する見込みです。例えば、抗凝固剤は僧帽弁疾患を管理し、脳卒中などの重篤な合併症を引き起こす可能性のある血栓を予防するために一般的に使用されています。そのため、抗凝固剤の採用が増加し、市場成長の原動力となっています。

さらに、僧帽弁疾患の発生率の上昇は、人口の高齢化や高血圧、糖尿病、肥満などの危険因子の増加など、いくつかの要因に起因しています。人口の高齢化に伴い、僧帽弁疾患を発症するリスクは増加します。これは、弁が時間の経過とともに傷ついたり弱くなったりすることで、誤作動を起こしやすくなるためです。また、高血圧や肥満などの危険因子の増加も僧帽弁疾患の発症リスクを高めます。さらに、患者や医療従事者の間で僧帽弁疾患に対する認識が高まり、早期診断・早期治療が行われるようになり、医療介入の需要が高まっています。世界中の政府が僧帽弁疾患の新たな治療法の研究開発に投資しているため、新規治療薬の開発が進んでいます。
加えて、僧帽弁疾患に関連する症状や危険因子に関する認知度の向上により、僧帽弁疾患の治療を求める人が増えており、これが市場の成長をさらに後押ししています。しかし、僧帽弁疾患に対する他の治療オプションが利用可能であることが、僧帽弁疾患治療薬市場の成長を抑制すると予想されています。僧帽弁疾患には、外科的介入や経カテーテル手技など、いくつかの代替治療オプションがあります。これらの代替オプションは、一部の患者に好まれる場合もあれば、個々の患者のニーズに基づいて医療提供者が推奨する場合もあり、市場の成長を抑制しています。

僧帽弁疾患治療薬の世界市場は、薬剤クラス、年齢層、流通チャネル、地域に区分されます。薬剤クラス別では、市場はβ遮断薬、利尿薬、抗凝固薬、その他に分類されます。年齢層別では、市場は55歳未満と55歳以上に分類されます。流通チャネル別では、病院薬局、ドラッグストアや小売薬局、オンラインプロバイダーに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）に分析されます。
世界の僧帽弁疾患治療薬市場で事業を展開する主な主要企業は、Zydus Lifesciences Limited、Pfizer Inc.、Bayer AG、Novartis AG、Viatris Inc.、Alembic Ltd.、Teva Pharmaceutical Industries Ltd.、Cipla Ltd.、Sun Pharmaceutical Industries Limited、Sanofiです。

ステークホルダーにとっての主なメリット
この調査レポートは、僧帽弁疾患治療薬市場の市場機会を特定するために、2022年から2032年までの市場セグメント、現在の動向、予測、および市場分析のダイナミクスを定量的に分析します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
僧帽弁疾患治療薬市場のセグメンテーションの詳細分析により、市場機会を見極めます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
僧帽弁疾患治療薬の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主な市場セグメント
流通チャネル別
病院薬局
ドラッグストアおよび小売薬局
オンラインプロバイダー

薬剤クラス別
β遮断薬
利尿薬
抗凝固薬
その他

年齢層別
55歳未満
55歳以上

地域別
北米
アメリカ
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Bayer AG
○ Novartis AG
○ Teva Pharmaceutical Industries Ltd.
○ Pfizer Inc.
○ Viatris Inc.
○ Sun Pharmaceutical Industries Limited
○ Cipla Ltd
○ Zydus Lifesciences Limited
○ Sanofi
○ Alembic Ltd

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：僧帽弁疾患治療薬市場、薬剤クラス別
第5章：僧帽弁疾患治療薬市場、年齢層別
第6章：僧帽弁疾患治療薬市場、流通チャネル別
第7章：僧帽弁疾患治療薬市場、地域別
第8章：競争状況
第9章：企業情報

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increasing prevalence of mitral valve diseases
3.4.1.2. Rise in adoption of pharmaceutical drugs to manage mitral valve disease symptoms
3.4.1.3. Rise in geriatric population

3.4.2. Restraints
3.4.2.1. Availability of alternative treatment options

3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Beta blockers
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Diuretics
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Anticoagulants
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market size and forecast
5.2. Below 55 years
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Above 55 years
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug store and retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug class
7.2.3. Market size and forecast, by Age group
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug class
7.2.5.1.3. Market size and forecast, by Age group
7.2.5.1.4. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug class
7.2.5.2.3. Market size and forecast, by Age group
7.2.5.2.4. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug class
7.2.5.3.3. Market size and forecast, by Age group
7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug class
7.3.3. Market size and forecast, by Age group
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug class
7.3.5.1.3. Market size and forecast, by Age group
7.3.5.1.4. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug class
7.3.5.2.3. Market size and forecast, by Age group
7.3.5.2.4. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug class
7.3.5.3.3. Market size and forecast, by Age group
7.3.5.3.4. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug class
7.3.5.4.3. Market size and forecast, by Age group
7.3.5.4.4. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug class
7.3.5.5.3. Market size and forecast, by Age group
7.3.5.5.4. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug class
7.3.5.6.3. Market size and forecast, by Age group
7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug class
7.4.3. Market size and forecast, by Age group
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug class
7.4.5.1.3. Market size and forecast, by Age group
7.4.5.1.4. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug class
7.4.5.2.3. Market size and forecast, by Age group
7.4.5.2.4. Market size and forecast, by Distribution channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug class
7.4.5.3.3. Market size and forecast, by Age group
7.4.5.3.4. Market size and forecast, by Distribution channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug class
7.4.5.4.3. Market size and forecast, by Age group
7.4.5.4.4. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug class
7.4.5.5.3. Market size and forecast, by Age group
7.4.5.5.4. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug class
7.4.5.6.3. Market size and forecast, by Age group
7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug class
7.5.3. Market size and forecast, by Age group
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug class
7.5.5.1.3. Market size and forecast, by Age group
7.5.5.1.4. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug class
7.5.5.2.3. Market size and forecast, by Age group
7.5.5.2.4. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug class
7.5.5.3.3. Market size and forecast, by Age group
7.5.5.3.4. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug class
7.5.5.4.3. Market size and forecast, by Age group
7.5.5.4.4. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Zydus Lifesciences Limited
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Pfizer Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Bayer AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Novartis AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Viatris Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Alembic Ltd
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Limited
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Cipla Ltd
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Teva Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Sanofi
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BETA BLOCKERS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DIURETICS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 07. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 10. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 18. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 19. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 20. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 22. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 23. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 25. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 26. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 28. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 29. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 31. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 32. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 33. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 35. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 36. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 37. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 38. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 39. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 41. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 42. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 44. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 45. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 53. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 54. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 55. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 57. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 58. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 60. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 61. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 71. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 72. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 73. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 75. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 76. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 77. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 87. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 88. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 89. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 90. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 91. PFIZER INC.: KEY EXECUTIVES
TABLE 92. PFIZER INC.: COMPANY SNAPSHOT
TABLE 93. PFIZER INC.: PRODUCT SEGMENTS
TABLE 94. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 95. BAYER AG: KEY EXECUTIVES
TABLE 96. BAYER AG: COMPANY SNAPSHOT
TABLE 97. BAYER AG: PRODUCT SEGMENTS
TABLE 98. BAYER AG: PRODUCT PORTFOLIO
TABLE 99. NOVARTIS AG: KEY EXECUTIVES
TABLE 100. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 101. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 102. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 103. VIATRIS INC.: KEY EXECUTIVES
TABLE 104. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 105. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 106. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 107. ALEMBIC LTD: KEY EXECUTIVES
TABLE 108. ALEMBIC LTD: COMPANY SNAPSHOT
TABLE 109. ALEMBIC LTD: PRODUCT SEGMENTS
TABLE 110. ALEMBIC LTD: PRODUCT PORTFOLIO
TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 115. CIPLA LTD: KEY EXECUTIVES
TABLE 116. CIPLA LTD: COMPANY SNAPSHOT
TABLE 117. CIPLA LTD: PRODUCT SEGMENTS
TABLE 118. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 123. SANOFI: KEY EXECUTIVES
TABLE 124. SANOFI: COMPANY SNAPSHOT
TABLE 125. SANOFI: PRODUCT SEGMENTS
TABLE 126. SANOFI: PRODUCT PORTFOLIO

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 僧帽弁疾患治療薬の世界市場2023-2032：機会分析・産業予測(Mitral Valve Disease Therapeutics Market By Drug class (Beta blockers, Diuretics, Anticoagulants, Others), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 重症筋無力症治療の世界市場2023-2032：機会分析・産業予測
  • 線維筋痛症治療の世界市場2023-2032：機会分析・産業予測
  • 網膜生物製剤の世界市場2023-2032：機会分析・産業予測
  • 駆虫剤の世界市場2023-2032：機会分析・産業予測
  • インクレチン系薬剤の世界市場2023-2032：機会分析・産業予測

    • ◆H&Iグローバルリサーチのお客様（例）◆